Magnetic resonance and rapid brain stimulation for Long COVID cognitive and mood symptoms
Official title: Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation (MANIFEST)
Run by University of New Mexico · NCT06940609 · Data updated 2026-11-12
This trial will test whether an accelerated outpatient magnetic brain stimulation (iTBS) can help reduce brain fog, depression, and anxiety in adults with Long COVID.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | University of New Mexico Academic / other |
| Locations | 1 site (Albuquerque, New Mexico) |
| Status | Recruiting |
| Started | July 7, 2025 |
| Main results expected | June 30, 2029 |
| Study ends | June 30, 2029 |
| Registry record updated | July 15, 2026 |
| Trial ID | NCT06940609 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–80 with a documented diagnosis of PASC who have ongoing cognitive symptoms such as brain fog, are fluent in English, and on stable psychotropic medications if applicable.
✕Probably not a fit
People with a history of seizures, psychotic disorders, active substance dependence, implanted electrical devices, recent medical hospitalization, or those without cognitive complaints are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, sham-controlled Phase 2 trial delivering accelerated intermittent theta burst stimulation (iTBS) to individualized brain targets in people with neuro-PASC. Participants receive multiple daily outpatient iTBS sessions over a course of treatment with a blinded phase followed by open-label sessions. Symptom surveys, cognitive tests, and MRI scans (including measures of brain choline as a marker of inflammation) are collected at baseline, mid-treatment, and end-of-treatment. Investigators will compare symptom change between active and sham groups and correlate clinical improvements with imaging measures.
Why it matters
Potential benefit: If effective, this approach could reduce cognitive and mood symptoms of Long COVID and improve daily functioning and quality of life.
How similar studies have gone: Related rTMS/iTBS approaches have shown benefit for depression and some cognitive symptoms, but application to Long COVID is novel and supported only by limited preliminary data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. aged 18-80 2. a documented diagnosis of PASC with evidence of ongoing symptoms as demonstrated by score of 12 on the NIH RECOVER Symptom List 3. have "brain fog" or cognitive difficulties as one of the ongoing symptoms 4. are fluent in English 5. if taking psychotropic medications, have been on stable doses for the past month. Exclusion Criteria: 1. a prior history of other neurological disease, or any history of seizures, so as to reduce risk of exacerbation of epilepsy or other neurological symptoms; 2. history of a psychotic disorder, such as schizophrenia or bipolar disorder, so as to reduce risk of psychiatric decompensation 3. history of ongoing substance/alcohol dependence, to reduce confounding effects on diagnosis and brain imaging 4. presence of any implanted electrical device (e.g., pacemaker), to reduce risk of device malfunction from rTMS 5. recent medical hospitalization (within four weeks), to reduce risk of medical decompensation during the study 6. any condition that would prevent the subject from completing the protocol 7. appointment of a legal representative, to avoid coercion of a vulnerable population 8. any ongoing litigation related to medical diagnosis, or disability, to prevent interference with legal proceedings 9. any contraindication to MRI 10. membership in an identified vulnerable population, including minors, pregnant women, and prisoners, so as to prevent coercion.
Where it's running
-
University of New Mexico Health Science Center
Albuquerque, New Mexico, United States Recruiting
Study contacts
- Principal investigator: Davin Quinn, MD — University of New Mexico
- Study coordinator: Crystal Garcia
- Email: crabaca@salud.unm.edu
- Phone: 505-272-9552
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Immunoadsorption blood filter for autoimmune long COVID
We will test a blood-filter treatment called immunoadsorption in people with long COVID who have specific autoantibodies to see if their fatigue and daily functioning get better.
-
Effects of Osteopathic Manipulative Therapy on Long COVID symptoms
This study is testing whether Osteopathic Manipulative Therapy can help people with Long COVID feel better by reducing their symptoms over eight weeks.
-
Magnetic brain stimulation for fatigue and brain fog in long COVID
This trial will see if repetitive transcranial magnetic stimulation (rTMS) can reduce severe fatigue and improve concentration in adults with long COVID.
-
Anktiva for treating Long COVID symptoms
This will test whether Anktiva helps adults aged 18–69 who had confirmed COVID-19 and now have persistent or worsened Long COVID symptoms.
-
Functional and cognitive rehabilitation versus informational support for adults with Long COVID and chronic conditions
This trial will try a combined physical and cognitive rehab program versus weekly evidence-based messages to see if adults with Long COVID and pre-existing hypertension or diabetes walk farther, think clearer, and feel better overall.
-
Analyzing MicroRNAs and Vitamin B12 in Long COVID Patients with Neurological Symptoms
This study is testing if changes in certain microRNAs and vitamin B12 levels in the blood can help understand and treat neurological symptoms like depression and fatigue in people who have long COVID.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.